51. 全身性強皮症 Scleroderma Clinical trials / Disease details

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04200755 (ClinicalTrials.gov)	May 19, 2020	10/12/2019	Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma	A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma	Localized Scleroderma	Drug: Dupilumab 300Mg Solution for Injection;Other: Placebo	University of Cologne	NULL	Recruiting	18 Years	N/A	All	45	Phase 2	Germany
2	EUCTR2019-002036-90-DE (EUCTR)	02/12/2019	02/10/2019	Study to test effectiveness and safety of the drug Dupilumab in patients with localized scleroderma	A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma - DupiMorph	Localized scleroderma MedDRA version: 21.1;Level: LLT;Classification code 10009206;Term: Circumscribed scleroderma;System Organ Class: 100000004859 MedDRA version: 21.0;Classification code 10018124;Term: Generalized scleroderma;System Organ Class: 100000004859 MedDRA version: 20.0;Classification code 10027979;Term: Morphea;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Product Name: Dupilumab Product Code: Dupilumab INN or Proposed INN: Dupilumab Other descriptive name: SAR231893	University of Cologne	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 2	Germany